Compare AbCellera Biologics Inc (ABCL) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Indonesia Energy Corporation Limited — how do they compare? AbCellera Biologics Inc trades at $7.25 (market cap $2.35B), while Indonesia Energy Corporation Limited trades at $2.8 (market cap $44.31M). The key difference: AbCellera Biologics Inc is far larger — about 53× Indonesia Energy Corporation Limited's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| ABCL | INDO | |
|---|---|---|
Market Cap | $2.35B | $44.31M |
Sector | Health | Energy |
52-Week High | $8.12 | $6.74 |
52-Week Low | $2.78 | $2.49 |
Enterprise Value | $1.99B | $39.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
INDO trades at $2.79 with no recent price movement. The stock shows mixed technical signals with a bullish overall rating but bearish moving averages. Fundamentally, the company reported negative profitability metrics with a -253.4% net income margin on $2M revenue in 2025, though recent news highlights operational progress with new well drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of drilling operations to improve financial performance. Key opportunities include potential revenue growth from new wells, while risks center on continued negative cash flow and profitability challenges. The stock presents speculative potential for investors betting on operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
